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Abstract.  – OBJECTIVE: Eribulin mesylate 
(Halaven®) is a non-taxane inhibitor of micro-
tubule indicated as monotherapy in patients 
with metastatic breast cancer (MBC), which pro-
gresses after anthracycline and taxanes thera-
py. In this retrospective observational study, we 
want to evaluate the efficacy of Eribulin in elder-
ly women with MBC pretreated with anthracy-
clines and taxanes.
PATIENTS AND METHODS: 40 elderly pa-
tients > 70 years of age were enrolled, and the 
median age was 76 years (range 70-82). Overall 
survival (OS), Progression Free Survival (PFS), 
Objective Response Rate (ORR) were primary 
endpoints, tolerability, carcinoembryonic anti-
gen levels 15.3 (Ca 15.3), before and after treat-
ment, and Quality of Life (QoL) were secondary 
endpoints.
RESULTS: Eribulin treatment was well tolerat-
ed, produced a good level of disease control, a 
manageable toxicity profile and a significant im-
pact on QoL. Median OS was 12.8 months and 
median PFS was 3.2 months. A significant cor-
relation was observed between reduction of Ca 
15.3 and PFS with a value of 0.59 (p = 0.002).
CONCLUSIONS: Despite a limited number 
of patients and a modest manageable toxicity, 
Eribulin is a chemotherapy treatment that has 
showed to be an effective and well-tolerated 
therapeutic option in elderly patients with MBC. 
Further analysis should focus on the elderly pa-
tients in our setting of study.
Key Words: 
Halaven, Metastatic breast cancer, Elderly patients, 
Survival, Ca 15.3, Quality of life.
Introduction
Breast cancer is the most diagnosed neoplasm 
and the main cause of death in female population, 
both in industrialized and developing countries. 
30% of breast cancer patients are diagnosed over 
70 years old and recent data suggest a continu-
ous increase in older women1. The probability of 
developing breast cancer is 2.3% up to 49 years, 
5.4% between 50 and 69 years old, and 4.5% be-
tween 70 and 84 years old2. Therapeutic objective 
in elderly patients with metastatic breast cancer 
(MBC) is palliative and mainly consists of con-
trolling symptoms, prolonging survival and im-
proving Quality of Life (QoL)3,4. Anthracyclines 
and taxanes are the most commonly used drugs 
in MBC and after their failure, there aren’t gold 
standard of cure. In elderly patients, single agent 
therapy is generally preferred to poly-chemo-
therapy, because this is associated at multiple 
side effects5,6. Eribulin (Eisai GmbH, Frankfurt, 
Germany) is an irreversible microtubule growth 
inhibitor, no taxane, with a new mechanism that 
blocks mitosis in G2-M phase, inducing apop-
tosis7-9. In EMBRACE trial, Eribulin treatment 
conferred a significant survival advantage com-
pared with treatment of physician’s choice (TPC) 
with a manageable toxicity profile. The Embrace 
study demonstrated a significant prolongation of 
overall survival with good tolerability in MBC. 
The median overall survival in patients treated 
with Eribulin was 13.2 months vs. 10.6 months 
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in control arm (p = 0.04), with other treatment 
of physician’s choice with 19% reduction in mor-
tality risk (HR 0.81, 95% CI 0.66-0.99). Further-
more, the drug has been shown to offer significant 
benefits also in terms of progression free survival 
(3.7 months vs. 2.2) and the overall response rate 
(12.2% vs. 4.7%). Age is not a potential factor in 
increasing toxicity or reducing Eribulin efficacy. 
Eribulin improved overall survival with manage-
able toxicity in elderly patients with MBC. There-
fore, age alone should not preclude consideration 
of Eribulin for patients > 70 years of age10,11,5. De-
spite the high incidence of this disease in older 
women, the number of clinical studies conducted 
specifically for this population unfortunately re-
mains limited. The current therapeutic approach 
for elderly patients with MBC is very similar to 
that of younger patients. Eribulin has been shown 
to be effective in prolonging the survival of el-
derly patients with MBC HER2 negative, with 
manageable toxicity. A post-hoc analysis, the ES-
EMPiO study, in older patients with MBC, could 
benefit of Eribulin treatment in a similar way than 
their younger counterparts. The efficacy of Eribu-
lin treatment in older patients was similar to that 
reported for overall ESEMPiO population with an 
OS to 11.6 months and PFS to 4.1 months12-14. 
Study Design 
This retrospective observational study was 
conducted to evaluate therapeutic benefits and 
tolerability profiles of Eribulin in elderly patients 
with MBC after the failure of anthracyclines and 
taxanes. Overall Survival (OS), Progression Free 
Survival (PFS), Objective Response Rate (ORR), 
were primary endpoints, tolerability, reduction of 
Carcinoembryonic Antigen 15.3 (Ca 15.3) levels, 
before and after treatment, and Quality of Life 
(QoL) were secondary endpoints. The research 
was conducted in accordance with the principles 
of Helsinki Declaration and good clinical practice 




This study was approved by the Ethics Com-
mittee Palermo 1. In this study, we enrolled a total 
of 40 patients with over age of 70 years, and diag-
nosed with MBC between Jun 2018 and Jun 2019. 
All patients enrolled in the study provided written 
informed consent and were selected according to 
the following inclusion criteria: 1) histological or 
cytological confirmed breast cancer with measur-
able or evaluable disease; 2) unresectable stage IV 
cancer pretreated with conventional anthracycline 
and taxanes therapies; 3) age over 70 years old; 4) 
performance score status between 0 and 1 accord-
ing to the Eastern Cooperative Oncology Group 
(ECOG); 5) life expectancy of > 3 months; 6) reg-
ular heart function with left ventricular ejection 
fraction at rest (LVEF) > 50% and sinus rhythm 
on the Electrocardiogram (ECG); 7) clinical or 
radiological evidence of metastatic measurable 
disease by spiral computer tomography (CT) scan 
or magnetic resonance imaging (MRI) scan, in 
accordance with Response Evaluation Criteria in 
Solid Tumors (RECIST) version 1.1, with a num-
ber of lesions ≥ 1; 8) with the following laboratory 
results: neutrophils 2.0×109/L; platelets 100×109/L; 
hemoglobin 10 g/dL; creatinine, 1 mg/dL, the up-
per limit of the standard (ULN); creatinine clear-
ance > 60 mL/min if creatinine was above the in-
dicated limit; bilirubin, 1×ULN; aspartate amino-
transferase (AST) and alanine aminotransferase 
(ALT) 5×ULN; and alkaline phosphatase, 5×ULN 
(except in presence of bone metastases). Patients 
with asymptomatic central nervous system metas-
tases were approved, and treatment with surgery 
or radiation therapy of brain lesions should have 
been completed no more than 3 months before 
study entry. As in previous studies15-17, exclusions 
criteria were as follows: 1) patients hypersensitive 
to Eribulin and its excipients or to other compo-
nents of formulation; 2) patients with a diagnosis 
of other malignancies, with exception of skin bas-
al cell carcinoma, adequately treated; 3) patients 
with symptomatic brain metastases; 4) patients 
presenting severe co-morbidities not adequately 
controlled by other ongoing therapies (e.g. liver 
disease, diabetes, infections, heart disease, etc.). 
Other concomitant anticancer therapies were not 
admitted, and radiotherapy to extracranial sites or 
hormonal therapy should have been terminated at 
least 1 month before starting Eribulin treatment. 
Method of Administration
All patients received Eribulin 1.23 mg/m2 in-
travenously over 2-5 minutes, on days 1 and 8 of 
each 21-day cycle13. Dose reduction (0.62 mg/m2) 
has been performed to manage treatment related 
toxicity; discontinuation occurred with unman-
ageable toxicity. Patients were premedicated at 
least thirty minutes before infusion, with steroid 
(dexamethasone sodium phosphate), antiemetic, 
antihistamine and with H2 antagonists. Further-
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more, during the entire treatment period, ade-
quate hydration was advised to patient in order 
to prevent complications such as renal failure. 
Treatment was given until disease progression or 
the development of unacceptable toxicity or pa-
tient rejection. Basic laboratory assessments were 
made 14 days before enrollment and during the 
treatment. Grade 3 or 4 toxic effects were man-
aged with dose modifications or delaying days of 
drug infusion and according to clinical practice 
procedures. Therapy was postponed for up to 2 
weeks if neutrophil count was < 1.5×109/L prior or 
if platelet count was < 100×109/L, if hemoglobin 
level was < 8.5 g/dl, or if bilirubin and/or amino-
transferase levels were > 1.5×ULN. In the case of 
neutropenia (G3-G4) G-CSF under the skin was 
also administered in advance. In the case of ane-
mia (G4) blood transfusions were performed or, 
in less severe cases (G2-G3) erythropoietin vials 
under skin, and finally for major thrombocytope-
nia (G2-G3) steroid therapy or (G4) intravenous 
platelet infusion. Concomitant treatments that did 
not interfere with the evaluation of Eribulin, such 
as bisphosphonates or denosumab, were adminis-
tered. Electrocardiogram (ECG) with QT interval 
measurement was repeated on day 8, every three 
cycles; hematological and chemical investigations 
were performed on first day and repeated on day 
8 and day before next cycle. Treatment continued 
until disease progression, unacceptable toxicity, 
or consent withdrawal. 
Evaluation on Response and Toxicity
Evaluation of response rate in terms measur-
able pathology reduction, in accordance with Re-
sponse Evaluation Criteria in Solid Tumors (RE-
CIST version 1.1)18, was conducted at beginning 
of treatment, and every 3 months until disease 
progression. The spiral CT scan, with and without 
contrast medium, was performed before the start 
of treatment, every three months until disease pro-
gression, or a presumed clinical progression. To-
tal body bone scintigraphy was always performed 
before treatment and a physician discretion or pa-
tient characteristics, every six or twelve months. 
PET total body was performed at the oncologist 
discretion or any suspected disease progression. 
In the case of brain metastases, a magnetic reso-
nance imaging (MRI) was performed every 6-12 
weeks. Ca15.3 was determined before the treat-
ment thereafter every three months. Furthermore, 
was evaluated the response percentage in terms 
of Ca 13.5, enzyme reduction by comparing the 
mean scores of serum Ca 15.3 levels, before and at 
treatment end. The Ca15.3 progression was con-
sidered as: an increase of Ca15.3 ≥ 25% compared 
to the baseline values,  in those patients who did 
not obtain a significant reduction (≥ 50%) of the 
serum Ca15.3 levels during treatment; an increase 
of ≥ 50% of the lowest level observed in patients 
who achieved a significant reduction (≥ 50%) of 
serum Ca15.3 levels during treatment. Treatment 
continued until the clinical benefit was observed 
or until treatment was no longer tolerated. Treat-
ment-related toxicity (DRT) and side effects were 
assessed at the end of each cycle and reported 
in line with the Cancer Therapy Evaluation Pro-
gram, Common Terminology Criteria for Adverse 
Events (CTCAE), Version 4.0. 
Quality of Life Value 
QoL was routinely assessed to all patients, at 
start of treatment and at first follow-up, through 
the administration of a questionnaire by psy-
cho-oncologist. The questionnaire EORTC 
QLQ-C30 (European Organization for Research 
and Treatment of Cancer)14 is composed of both 
multi-item scales and single-item measures. 
There are five functional scales (physical, role, 
cognitive, emotional, and social), three symptom 
scales (fatigue, pain, and nausea and vomiting), 
a global health status/QoL scale, and six single 
items (dyspnea, loss of appetite, insomnia, con-
stipation, diarrhea and perceived financial impact 
of the disease). A higher scale score represents 
a higher response level. Thus, a high score for a 
functional scale represents a high/healthy level of 
functioning, a high score for global health status/
QoL represents a high QoL, but a high score for 
a symptom scale/item represents a high level of 
symptomatology/problems.
Statistical Analysis 
Statistical analysis was performed using Statis-
tical Package for Social Science (SPSS) software 
version 24.0 for Mac (IBM Corp., Armonk, NY, 
USA). Standard descriptive statistics were use-
ful for providing a clinical data representation 
and distribution of all variables. The normality 
of distribution was checked using the univariate 
skewness and kurtosis indices with an accep-
tance threshold equal to 1. All the variables were 
conformed to the normality indexes. The rate of 
disease control was defined as the percentage of 
patients with an objective response and/or stable 
disease > 6 months. OS was evaluated from start 
of treatment until death for any cause, PFS was 
calculated from start of treatment until progres-
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sion disease. OS and PFS curve were estimated 
using the Kaplan-Meier method. Last follow-up in 
June 2020. Bravais-Pearson (r) linear correlation 
index was used to quantify the relation between 
PFS and Ca 15.3 with 95% confidence interval 
(CI). The statistical significance was defined as a 
p-value of less than 0.05. 
Results
Characteristic of Patients 
The study included 40 patients with MBC, the 
average age was 76 years (range 70-82), the demo-
graphic and clinic-pathological characteristics are 
shown in Table I. All patients were metastatic and 
were HER2 negative, twenty-eight patients had 
positive estrogen (ER) and progesterone (PR) re-
ceptors; twelve patients had negative estrogen (ER) 
and progesterone (PR) receptors; twelve patients 
had triple negative tumors. All Italian patients 
were white and postmenopausal. Patients with Per-
formance Status (Eastern Cooperative Oncology 
Group) ECOG 0 were 16 and ECOG 1 were 24. 
Patients with an ECOG 2 or more were excluded. 
The localization of metastasis was: 18 patients had 
bone metastases; 12 have liver metastases; 16 have 
lung metastases; 26 have  lymph node metastases, 
and 6 patients other. All patients had received an-
thracycline and taxanes regimens before starting 
Eribulin, 46% in an adjuvant setting and 54% in 
metastatic. All patients enrolled with positive hor-
mone receptors received hormone therapy. Two 
patients performed thermal ablation on liver me-
tastases and no patients died from treatment-re-
lated adverse events. Moreover, no patients were 
hospitalized and the adverse advent was managed 
generally on an outpatient basis.
 OS and PFS Analysis 
Among 40 patients enrolled in this study, the 
Kaplan-Meier method showed a median OS anal-
ysis value of 12.8 months (95% CI: 11.2-14.00) 
(Figure 1) and a median PFS value of 3.2 months 
(95% CI: 2.8-5.4) (Figure 2).
Objective Response Rate Analysis
Our analysis shows that treatment was well-tol-
erated in all patients with a good level of disease 
control (PR + SD > 50%). The median response 
time was 3.8 months (95% CI: 1.7 - 7.2), after an 
average follow-up duration of 12.1 months (range 
3-18) with a significant impact on clinical bene-
fits and an improvement of QoL. No patients had 
a complete response (CR); 18% had a partial re-
sponse (PR), 40% had disease stabilization (SD) 
38% of patients had disease progression (PD). 
Eribulin mesylate treatment was well-tolerated 
and led to a good level of disease control (PR + 
SD > 50%). 
Ca15.3 Reduction 
A Bravais-Pearson index demonstrated a good 
correlation between PFS and Ca 15.3 reduction 
with a r (95% CI: 0.28 - 0.86) value of 0.59, p = 
0.002 (Table II). In particular, the reduction of 
Ca15.3 was > 50%, and we further demonstrated 
that this reduction was linked to an increase in 
Figure 1. Median Overall Survival (OS) with Kaplan-
Meier plot (n. 40).
Figure 2. Median Progression Free Survival (PFS) with 
Kaplan-Meier plot (n. 40).
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PFS. The reduction of Ca15.3 has been demon-
strated in patients with a greater response to treat-
ment.  
Quality of Life Value
At baseline (start treatment), the scores of ques-
tionnaires EORTC QLQ-C30 described a general 
QoL slightly low (score for global health status 
was 64.53 ± 21.98). At follow up the score was 
higher (79.93 ± 25.76). In the symptom scales, pa-
tients reported sleeping problems (15.85 ± 31.10), 
fatigue (23.76 ± 19.75), and pain (12.63 ± 22.98). 
The improvement of the quality of life was iden-
tified, at follow-up with a reduction of pain symp-
toms and an improvement of general health status 
in 47% of patients. The patients reported pain due 
to skeletal metastases and they were treated with 
non-opioid analgesics and, in some cases, with ra-
diation therapy.
Tolerability 
Treatment-related toxicity was well tolerated, 
and adverse events were assessed after each course 
of therapy and reported in line with CTCAE ver-
sion 4.0. No patient died from treatment-related 
adverse events. Hematological toxicity was one 
of the main complications managed with dose 
adjustment or reduction. Eleven patients (27.5%) 
developed G3-G4 neutropenia which required 
use of G-CSF as prophylaxis. Two patients (5%) 
developed febrile neutropenia which required the 
use of antibiotics and G-CSF. One patient devel-
oped grade G3 thrombocytopenia which required 
the use of corticosteroids; three patients (7.5%) 
developed G3 anemia which required the admin-
istration of erythropoietin under skin. All G4 tox-
icity effects were managed by dose modifications. 
The dose was reduced in five patients and it was 
postponed in three patients. Due to deteriorating 
clinical conditions, advanced age and comorbidi-
ties, one patient stopped treatment after three in-
fusions. One patient received 80% Eribulin from 
the first cycle due to clinical conditions. Only one 
patient showed asymptomatic prolongation of 
the QT interval but overall Eribulin showed no 
side effects on the cardiovascular system. Oth-
er toxicities were peripheral neuropathy G2-G3 
in five patients; asthenia/fatigue G2-G3 in seven 
patients; alopecia (G3-G4) in one patient; muco-
sitis and constipation G2-G3 in three patients; 
Table I. Baseline demographic and clinical characteristics 
(n = 40).
Characteristic All patients
Mean age [range] 76 [70-82]




 ER and PR (+) 28
 ER and PR (-) 12
 Triple Negative  12
Median Ca 15.3




 Bone 18  
 Lymph nodes 26
 Other 6
Note: ECOG = Eastern Cooperative Oncology Group; ER= 
estrogen receptors; PR = progesterone receptors. 
Table II. Pearson’s correlation among Ca15.3 and Progression 
Free Survival (PFS) (n = 40).
 Ca15.3 PFS p
Ca15.3 1  -0.59** 0.002
PFS -0.59** 1 0.002
Note: Ca15.3 = Carbohydrate Antigen 15-3; PFS = Progression 
Free Survival; **p < 0.01.
Table III. PAdverse events graded according CTCAE, Version 
4.0 (n = 40).
Adverse Events All Grades Grade 3-4                 
Anemia 8 (20%) 3 (7.5%)
Neutropenia 23 (57.5%) 11 (27.5%)
Thrombocytopenia  3 (7.5%) 1 (2.5%)




Constipation 5 (12.5%) 2 (5%)
Fatigue 9 (22.5%) 5 (12.5%)
Alopecia 12 (30%) 1 (2.5%)
 Stomatitis/mucositis 6 (15%) 2 (5%)
 Peripheral neuropathy  4 (10%) 2 (5%)
 Bone pain 8 (20%)  2 (5%)
Note: CTCAE = Common Terminology Criteria for Adverse 
Events.
R. De Luca, M. Alù, G. Genova, A. Grassadonia, G. Cicero
12732
increased transaminases (G2-G3) and bilirubin 
(G2-G3) in four patients. But no patients stopped 
treatment for serious side effects and no patients 
died from Eribulin treatment. The events associ-
ated with the treatment of toxicity and side effects 
are described in Table III.
Discussion
In recent years, 22% of new breast cancer di-
agnoses and 14% of breast cancer deaths concern 
women over the age of 70 years. In elderly pa-
tients, the chosen treatment is generally mono che-
motherapy to be preferred to poly-chemotherapy, 
with which multiple side effects are associated. 
Treatment in elderly patients should not only aim 
to increase survival, but above all to control symp-
toms and preserve QoL20-22. Eribulin in this study 
showed a good tolerability profile and acceptable 
toxicities, similar to those reported in EMBRACE 
studies with young patients. An analysis of the 
subgroup of Embrace study and of the ESEMPiO 
study did not indicate age as a potential factor of 
increased toxicity or decreased efficacy of Eribu-
lin. The safety profile was similar between age 
groups, but adverse events leading to dose reduc-
tions, delays or discontinuation increased slightly 
with age23,24,13. Dose reductions were permitted to 
manage treatment related adverse events accord-
ing to drug guidelines25,26. Consistent with litera-
ture, this study, also with a small sample, confirm 
that Eribulin monotherapy in elderly patients > 70 
years and highly pretreated has led to an improve-
ment in OS and PFS27, with a manageable toxicity 
profile among the elderly28,29 which did not differ 
from that described in younger patients. The data 
from this study showed an improvement in me-
dian OS of 12.8 months and median PFS was 3.2 
months and with a good level of disease control 
>50% without particularly significant adverse ef-
fects and with a good profile safety, suggesting 
that it could a potential treatment option for heav-
ily elderly patients. Considering adverse events 
associated with therapy appeared no greater in 
elderly patients, compared with younger patients, 
age alone should not preclude the possibility of 
Eribulin treatment for older patients with MBC. 
However, it is important consider the perfor-
mance status of patient before starting Eribulin 
treatment, the drug should be used with caution 
in patients in ECOG2 or higher with patients 
who are most comorbidity. The management to 
toxicity and tolerability of most frequent adverse 
events which neutropenia, fatigue, and peripher-
al neuropathy contributed to maintaining a good 
QoL. The disease control and the tolerability 
profile contributed also to guaranteeing the QoL 
from the first doses of treatment. In the setting of 
metastatic disease, the QoL is an objective most 
importance, thus contributing to compliance ther-
apy and extending time to progression. Eribulin 
treatment can lead to an effective disease control 
and, in some cases, an important debulking in the 
presence of metastases, moreover, could consid-
ered as a suitable therapeutic option for elderly 
patients. Bearing in mind this is a retrospective 
analysis and the limited number of patients, our 
results can yield valid hypotheses for future stud-
ies. In several clinical studies, Eribulin monother-
apy in patients > 70 years of age has shown a good 
efficacy and a modesty tolerability, results similar 
shows in study with younger patients. Neutro-
penia, anemia, alopecia, fatigue and peripheral 
neuropathy have not been found more frequently 
in older patients than in younger patients, while 
other adverse events had a similar incidence30,31. 
Of clinical variables examined, those that had a 
significant impact favoring improved OS were 
having, an ER-positive and HER negative tumor. 
In addition, improved baseline performance sta-
tus is predictive of an improvement in the overall 
survival. The limitations of this analysis include 
the limited patients’ number and the non-random 
sampling of patients. The results provided some 
observations for daily clinical practice among 
older MBC patients who Eribulin is therefore a 
valid and effective treatment, well-tolerated and 
safe in elderly patients. Our results are consistent 
with those observed of ESEMPiO study, in phase 
III clinical trials (Studies 301 and 305), and in the 
subgroup of Embrace thus showing that Eribulin 
is a safe and feasible treatment also for elderly 
women with MBC13,28,29. 
Conclusions
We observed that use Eribulin in MBC elder-
ly patients > 70 years old, with HER2 negative, 
prolonged survival, confirming its efficacy in 
disease control with a response on metastatic le-
sions32. Adverse events associated with therapy 
appeared no greater in elderly patients, compared 
with younger patients, and age alone should not 
preclude the possibility of Eribulin treatment for 
older patients with MBC. Predictive factors per-
formance status and number of metastatic sites 
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were predictive factors of PFS, and discriminant 
function analysis (DFA) could be a promising 
tool to discriminate responses to Eribulin among 
MBC in elderly patients.
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